GKOS
Glaukos Corporation NYSE Listed Jun 25, 2015$134.13
After hrs
$133.52
+0.02%
Mkt Cap $7.9B
52w Low $73.16
82.9% of range
52w High $146.75
50d MA $115.47
200d MA $102.55
P/E (TTM)
-42.8x
EV/EBITDA
-43.3x
P/B
12.2x
Debt/Equity
0.2x
ROE
-28.6%
P/FCF
-119.6x
RSI (14)
—
ATR (14)
—
Beta
0.78
50d MA
$115.47
200d MA
$102.55
Avg Volume
713.5K
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
229 Avenida Fabricante · Aliso Viejo, CA 92672 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | AMC | -0.30 | -0.18 | +40.0% | 116.96 | +21.0% | +22.8% | +19.9% | +16.2% | +14.1% | +15.7% | — |
| Feb 17, 2026 | AMC | -0.22 | -0.28 | -27.3% | 106.64 | -2.9% | +13.5% | +9.8% | +12.8% | +12.9% | +11.7% | — |
| Oct 29, 2025 | AMC | -0.27 | -0.16 | +40.7% | 77.09 | +23.3% | +13.9% | +14.2% | +13.4% | +11.5% | +9.4% | — |
| Jul 30, 2025 | AMC | -0.26 | -0.24 | +7.7% | 94.05 | -0.6% | -8.5% | -8.4% | -7.0% | -6.4% | -5.9% | — |
| Apr 30, 2025 | AMC | -0.33 | -0.22 | +33.3% | 94.25 | -10.4% | -11.4% | -7.0% | -7.8% | -7.5% | -6.4% | — |
| Feb 20, 2025 | AMC | -0.38 | -0.40 | -5.3% | 157.36 | -10.2% | -20.0% | -21.0% | -23.4% | -23.4% | -24.8% | — |
| Nov 4, 2024 | AMC | -0.52 | -0.28 | +46.2% | 131.38 | -4.9% | -2.7% | +7.0% | +6.1% | +7.9% | +8.9% | — |
| Jul 31, 2024 | AMC | -0.52 | -0.52 | +0.0% | 117.17 | -5.2% | +0.4% | -1.0% | -3.0% | -0.4% | -1.1% | — |
| May 1, 2024 | AMC | -0.58 | -0.70 | -20.7% | 98.91 | -2.0% | +6.2% | +7.7% | +6.2% | +9.2% | +8.1% | — |
| Feb 21, 2024 | AMC | -0.56 | -0.63 | -12.5% | 92.79 | +3.0% | -1.4% | -3.5% | -1.3% | -2.5% | -3.0% | — |
| Nov 1, 2023 | AMC | -0.56 | -0.50 | +10.7% | 69.43 | -4.8% | -7.6% | -7.5% | -7.8% | -10.3% | -7.6% | — |
| Aug 2, 2023 | AMC | -0.57 | -0.55 | +3.5% | 74.72 | -2.1% | -0.4% | -0.4% | +0.6% | +0.1% | -3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Citigroup | Maintains | Buy → Buy | — | $116.96 | $141.50 | +21.0% | +22.8% | +19.9% | +16.2% | +14.1% | +15.7% |
| Apr 30 | Needham | Maintains | Buy → Buy | — | $116.96 | $141.50 | +21.0% | +22.8% | +19.9% | +16.2% | +14.1% | +15.7% |
| Apr 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $116.96 | $141.50 | +21.0% | +22.8% | +19.9% | +16.2% | +14.1% | +15.7% |
| Apr 30 | JP Morgan | Maintains | Overweight → Overweight | — | $116.96 | $141.50 | +21.0% | +22.8% | +19.9% | +16.2% | +14.1% | +15.7% |
| Apr 30 | BTIG | Maintains | Buy → Buy | — | $116.96 | $141.50 | +21.0% | +22.8% | +19.9% | +16.2% | +14.1% | +15.7% |
| Feb 18 | Needham | Maintains | Buy → Buy | — | $106.64 | $103.55 | -2.9% | +13.5% | +9.8% | +12.8% | +12.9% | +11.7% |
| Feb 18 | BTIG | Maintains | Buy → Buy | — | $106.64 | $103.55 | -2.9% | +13.5% | +9.8% | +12.8% | +12.9% | +11.7% |
| Feb 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $106.64 | $103.55 | -2.9% | +13.5% | +9.8% | +12.8% | +12.9% | +11.7% |
| Jan 28 | BTIG | Maintains | Buy → Buy | — | $118.70 | $122.10 | +2.9% | +4.4% | +0.3% | +0.6% | -1.0% | -0.5% |
| Jan 22 | Stifel | Maintains | Buy → Buy | — | $124.16 | $126.98 | +2.3% | +1.4% | -3.4% | +0.1% | -4.4% | -0.2% |
| Jan 14 | Needham | Maintains | Buy → Buy | — | $110.23 | $94.81 | -14.0% | -5.3% | +3.9% | +9.1% | +12.0% | +12.6% |
| Jan 2 | Stephens & Co. | Maintains | Overweight → Overweight | — | $112.91 | $114.47 | +1.4% | -1.9% | -0.4% | -0.6% | +0.7% | +1.1% |
| Jan 2 | BTIG | Maintains | Buy → Buy | — | $112.91 | $114.47 | +1.4% | -1.9% | -0.4% | -0.6% | +0.7% | +1.1% |
| Dec 23 | UBS | Maintains | Buy → Buy | — | $117.09 | $116.83 | -0.2% | -0.8% | -0.4% | -0.8% | -1.3% | -2.4% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $112.42 | $114.32 | +1.7% | +0.7% | +3.4% | +4.2% | +3.3% | +3.8% |
| Dec 11 | Citigroup | Maintains | Buy → Buy | — | $108.72 | $109.20 | +0.4% | +0.5% | +0.1% | +2.8% | +4.6% | +3.4% |
| Dec 9 | Needham | Maintains | Buy → Buy | — | $108.46 | $108.96 | +0.5% | -1.5% | +0.2% | +0.7% | +0.4% | +3.0% |
| Oct 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $77.09 | $95.07 | +23.3% | +13.9% | +14.2% | +13.4% | +11.5% | +9.4% |
| Oct 30 | Citigroup | Maintains | Buy → Buy | — | $77.09 | $95.07 | +23.3% | +13.9% | +14.2% | +13.4% | +11.5% | +9.4% |
| Oct 30 | BTIG | Maintains | Buy → Buy | — | $77.09 | $95.07 | +23.3% | +13.9% | +14.2% | +13.4% | +11.5% | +9.4% |
| Oct 30 | Needham | Maintains | Buy → Buy | — | $77.09 | $95.07 | +23.3% | +13.9% | +14.2% | +13.4% | +11.5% | +9.4% |
| Oct 30 | JP Morgan | Maintains | Overweight → Overweight | — | $77.09 | $95.07 | +23.3% | +13.9% | +14.2% | +13.4% | +11.5% | +9.4% |
| Oct 27 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $74.67 | $79.50 | +6.5% | +1.4% | +4.2% | +3.2% | +17.6% | +17.9% |
| Oct 20 | BTIG | Maintains | Buy → Buy | — | $87.17 | $88.80 | +1.9% | -8.8% | -13.0% | -12.1% | -13.7% | -14.3% |
| Oct 13 | BTIG | Maintains | Buy → Buy | — | $82.56 | $83.58 | +1.2% | +0.6% | +3.3% | +3.7% | +3.4% | +5.6% |
| Oct 7 | Citigroup | Maintains | Buy → Buy | — | $86.62 | $86.66 | +0.0% | -2.9% | +1.1% | +0.5% | -4.7% | -4.1% |
| Sep 22 | Truist | Maintains | Buy → Buy | — | $83.47 | $81.86 | -1.9% | +1.4% | +1.5% | -0.8% | -2.4% | -4.3% |
| Sep 10 | BTIG | Maintains | Buy → Buy | — | $90.91 | $90.37 | -0.6% | -3.7% | -3.8% | -9.0% | -11.3% | -9.4% |
| Jul 31 | UBS | Maintains | Buy → Buy | — | $94.05 | $93.50 | -0.6% | -8.5% | -8.4% | -7.0% | -6.4% | -5.9% |
| Jul 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $94.05 | $93.50 | -0.6% | -8.5% | -8.4% | -7.0% | -6.4% | -5.9% |
| May 6 | Morgan Stanley | Maintains | Underweight → Underweight | — | $86.86 | $85.13 | -2.0% | +0.4% | +1.6% | +4.2% | +3.6% | +9.0% |
| May 2 | Stephens & Co. | Maintains | Overweight → Overweight | — | $83.54 | $84.59 | +1.3% | +4.9% | +4.0% | +4.4% | +5.6% | +8.4% |
| May 1 | Stifel | Maintains | Buy → Buy | — | $94.25 | $84.42 | -10.4% | -11.4% | -7.0% | -7.8% | -7.5% | -6.4% |
| May 1 | Truist | Maintains | Buy → Buy | — | $94.25 | $84.42 | -10.4% | -11.4% | -7.0% | -7.8% | -7.5% | -6.4% |
| May 1 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $94.25 | $84.42 | -10.4% | -11.4% | -7.0% | -7.8% | -7.5% | -6.4% |
| May 1 | Needham | Maintains | Buy → Buy | — | $94.25 | $84.42 | -10.4% | -11.4% | -7.0% | -7.8% | -7.5% | -6.4% |
| Apr 16 | Mizuho | Maintains | Outperform → Outperform | — | $94.52 | $92.85 | -1.8% | -6.1% | -4.5% | -6.6% | -5.1% | -2.0% |
| Apr 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $92.91 | $93.03 | +0.1% | +1.7% | -4.4% | -2.9% | -5.0% | -3.4% |
| Apr 11 | Truist | Maintains | Buy → Buy | — | $89.66 | $89.66 | +0.0% | +0.5% | +3.6% | +5.4% | -1.0% | +0.7% |
| Feb 21 | Wells Fargo | Maintains | Overweight → Overweight | — | $157.36 | $141.35 | -10.2% | -20.0% | -21.0% | -23.4% | -23.4% | -24.8% |
| Feb 21 | Needham | Maintains | Buy → Buy | — | $157.36 | $141.35 | -10.2% | -20.0% | -21.0% | -23.4% | -23.4% | -24.8% |
| Feb 19 | Mizuho | Upgrade | Neutral → Outperform | — | $152.96 | $156.70 | +2.4% | +5.0% | +2.9% | -17.7% | -18.8% | -21.2% |
| Jan 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $160.22 | $159.21 | -0.6% | -2.0% | -0.3% | -0.8% | -1.5% | -2.4% |
| Dec 31 | Stifel | Maintains | Buy → Buy | — | $149.51 | $152.45 | +2.0% | +0.3% | +0.1% | +1.3% | +3.8% | +4.7% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $146.35 | $146.44 | +0.1% | -0.8% | -1.8% | +3.1% | +1.4% | +3.3% |
| Dec 11 | Citigroup | Upgrade | Neutral → Buy | — | $136.38 | $140.91 | +3.3% | +4.8% | +2.9% | +1.9% | +5.7% | +7.3% |
| Dec 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $136.38 | $140.91 | +3.3% | +4.8% | +2.9% | +1.9% | +5.7% | +7.3% |
| Dec 2 | Stifel | Maintains | Buy → Buy | — | $143.65 | $140.00 | -2.5% | -3.2% | -5.3% | -3.7% | -5.5% | -2.3% |
| Dec 2 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $143.65 | $140.00 | -2.5% | -3.2% | -5.3% | -3.7% | -5.5% | -2.3% |
| Nov 26 | BTIG | Maintains | Buy → Buy | — | $142.94 | $144.00 | +0.7% | -1.5% | -0.2% | +0.5% | -2.7% | -4.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | WEN LEANA | — | Sell | 1,700 | $143.35 | $244K | 19,739 | -1.79% | — |
| May 1, 2026 | Gilliam Joseph E | PRESIDENT & COO | Sell | 19,573 | $143.54 | $2.8M | 73,419 | -1.79% | — |
| Apr 30, 2026 | Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Sell | 10,000 | $140.00 | $1.4M | 43,681 | -1.79% | — |
8-K · 7.01
! Medium
Glaukos Corporation -- 8-K 7.01: Regulation FD Disclosure
Glaukos Corporation will present updated investor materials to stakeholders, with documents now publicly available on its investor relations website for transparency and accessibility.
May 4
8-K · 7.01
! Medium
Glaukos Corporation -- 8-K 7.01: Regulation FD Disclosure
Glaukos Corporation disclosed first-quarter 2026 supplemental financial information via 8-K filing, providing investors updated business metrics and performance data for the period ending March 31, 2026.
Apr 29
8-K · 7.01
! Medium
Glaukos Corporation -- 8-K 7.01: Regulation FD Disclosure
Glaukos Corporation disclosed investor presentation materials highlighting its business strategy and financial outlook to shareholders and stakeholders via regulatory filing.
Mar 2
8-K · 7.01
! Medium
Glaukos Corporation -- 8-K 7.01: Regulation FD Disclosure
Glaukos Corporation released supplemental Q4 2025 financial and business information through an 8-K filing, providing investors with detailed quarterly performance data on its investor relations website.
Feb 17
Data updated apr 25, 2026 11:31am
· Source: massive.com